Vaccines

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

A clinician discusses the vaccines' efficacy, which risk factors may rank higher for disease severity, and offers insights on counseling patients.

The emergency use listing (EUL) now provides another option for those who are in World Health Organization (WHO) member states.

Topline data results from the company’s phase 3 trial, STRIDE-3, were announced and will be presented at the World Vaccine Congress West Coast.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

The Pfizer product is indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

The federal agency says the data shows immunization reduces hospitalizations by more than 57 percent in first 6 months after birth.

The company says its vaccine protects against the BA286 strain.

The European Medicines Agency (EMA) based its decision on preclinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB15, XBB116, XBB23, and EG51.

The CDC reports the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Social media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.

The strain, Eris (EG5), is from the Omicron lineage, and the expectations are the newest vaccines will protect against it, and other variants from the same family.

The agency says additional time is needed to decide upon a phase 4 program.

The vaccine targets an additional 8 unique serotypes that disproportionally affect the adult population.

New report published this week shows the decrease over the last 2 reportable years.

Patients with cancer, cancer survivors, and matched controls maintained immunity against severe COVID-19 for at least 5 months after a third or fourth vaccine dose.

Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with lower COVID-19 rates.

This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.

Find out why the FDA requested additional data and what this means for dengue prevention.

Though rare, Guillain-Barré syndrome can occur after vaccination. Did Pfizer-BioNTech, Moderna, or Janssen COVID-19 vaccination increase the risk of Guillain-Barré syndrome?